Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:9/2/2015)... , Sep. 02, 2015 Research and Markets ... Affairs in Latin America (London, UK - November 16-18, 2015)" conference ... Latin America including Columbia, Peru ... Argentina , Uruguay , Paraguay ... Central America , Chile ...
(Date:9/2/2015)... , Sept. 2, 2015 Research ... addition of the "Medical Device Studies: Clinical ... conference to their offering. This ... are involved in gathering clinical evidence required for ... is required for all medical devices and the ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... 28, 2011  CIVCO Medical Solutions is introducing RAD-GUIDE, ... at RSNA 2011. RAD-GUIDE allows physicians a method ... visualizing and adjusting planned punctures prior to needle ... to translating our expertise in ultrasound needle guidance ...
... MAHWAH, N.J., Nov. 28, 2011 /PRNewswire-Asia-FirstCall/ -- ... a leading developer, manufacturer and marketer of medical devices ... DC-T6 ultrasound system at the annual Radiological Society of ... December 1, 2011 in Chicago. The new system is ...
Cached Medicine Technology:CIVCO Enters CT Needle Guidance Market with RAD-GUIDE™ Launch 2Mindray to Launch New DC-T6 Ultrasound System at RSNA 2Mindray to Launch New DC-T6 Ultrasound System at RSNA 3
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and educator ... and Associate Director of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) ... CDI Boot Camps. She serves as a CDI subject matter expert for a variety ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Administrators is taking action after seeing a significant increase in unlawful tactics ... Review division has found many cases of OON ASCs encouraging members to have ...
(Date:9/2/2015)... ... 2015 , ... The 2015 China Overseas Investment and Entrepreneurship ... conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai State ... feature leading EB-5 industry professionals and Chinese private equity partners looking for international ...
(Date:9/2/2015)... Kansas City, KS (PRWEB) , ... September 02, 2015 , ... ... recently opened its newest office in Kansas – its Johnson County location. ... backgrounds in healthcare. Mike has a registered nurse background and spent over 20 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... SonicSurg Innovations, an ... announced today that more than 600 successful patient procedures have been performed utilizing ... nearly 70 of these procedures have been on triggering thumbs. , SonicSurg ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2
... University of Colorado Boulder shows that today,s smokers are more ... that the influence makes it more difficult for them to ... people smoked for a variety of reasons," said sociology Professor ... smoking population has changed. Smokers are more likely to ...
... School of Medicine have identified hepcidin, a hormone that ... target for treating atherosclerosis. Suppressing hepcidin is a ... blood cells found in arterial plaques. Reducing iron levels ... a process called "reverse cholesterol transport," interfering with atherosclerosis, ...
... Walter and Eliza Hall Institute, Professor Doug Hilton, has ... Award. The award recognises Professor Hilton,s achievements as ... promoting the value of health and medical research to ... focussed on the control of blood formation. His research ...
... HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay News) -- ... immediately following the New York City terror attacks on Sept. ... warn. Those Ground Zero workers who got there first ... those who came on the scene after Sept. 13, and may ...
... WEDNESDAY, Nov. 16 (HealthDay News) -- One in five male breast ... effects caused by the medicine and may be at increased risk ... of care for the hormone treatment of male breast cancer patients, ... Nov. 16 issue of the Annals of Oncology . ...
... Among patients with stable cardiovascular disease who have a ... drug clopidogrel, tripling the standard daily dosage of this ... study appearing in JAMA . The study is ... at the American Heart Association Scientific Sessions. ...
Cached Medicine News:Health News:CU-Boulder led study of smoking twins points to growing influence of genetic factors 2Health News:Hormone that controls iron levels may be target for atherosclerosis treatment 2Health News:Professor Doug Hilton wins Research Australia Award 2Health News:9/11 First Responders May Face Greater Heart Risks 2Health News:9/11 First Responders May Face Greater Heart Risks 3Health News:Side Effects May Spur Men to Drop Tamoxifen for Breast Cancer 2Health News:Increasing dosage of clopidogrel for patients with genetic variation improves response to medication 2
Pilling-Weck, medium clip size, 10mm, rotatable take apart...
Pilling-Weck, small clip size, 10mm, rotatable take apart...
Insert only, Ethicon, medium clip size...
Ethicon, medium-large clip size, 10mm, rotatable take apart...
Medicine Products: